Eva Hernando

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7670996/publications.pdf

Version: 2024-02-01

60 papers	4,316 citations	218677 26 h-index	233421 45 g-index
60 all docs	60 docs citations	60 times ranked	7864 citing authors

#	Article	IF	Citations
1	A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis. Journal of Visualized Experiments, 2022, , .	0.3	1
2	Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis. Cancer Discovery, 2022, 12, 1314-1335.	9.4	31
3	In Vivo miRNA Decoy Screen Reveals miR-124a as a Suppressor of Melanoma Metastasis. Frontiers in Oncology, 2022, 12, 852952.	2.8	2
4	The histone demethylase PHF8 regulates TGFÎ² signaling and promotes melanoma metastasis. Science Advances, 2022, 8, eabi7127.	10.3	17
5	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.0	53
6	Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis. Nature Communications, 2021, 12, 1214.	12.8	27
7	HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. ELife, 2021, 10, .	6.0	27
8	Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. Journal of Translational Medicine, 2021, 19, 47.	4.4	10
9	Functional analysis of RPS27 mutations and expression in melanoma. Pigment Cell and Melanoma Research, 2020, 33, 466-479.	3.3	14
10	Tsc1 Regulates the Proliferation Capacity of Bone-Marrow Derived Mesenchymal Stem Cells. Cells, 2020, 9, 2072.	4.1	7
11	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	9.4	145
12	Human genes differ by their UV sensitivity estimated through analysis of UVâ€induced silent mutations in melanoma. Human Mutation, 2020, 41, 1751-1760.	2.5	0
13	Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell, 2020, 37, 55-70.e15.	16.8	200
14	circSamd4 represses myogenic transcriptional activity of PUR proteins. Nucleic Acids Research, 2020, 48, 3789-3805.	14.5	60
15	A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. Molecular Cancer Research, 2019, 17, 109-119.	3.4	28
16	Characterization of MicroRNAs Regulating FOXO Expression. Methods in Molecular Biology, 2019, 1890, 13-28.	0.9	1
17	miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Research, 2018, 78, 1017-1030.	0.9	140
18	Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability. Cell Death and Differentiation, 2018, 25, 935-950.	11.2	40

#	Article	IF	Citations
19	Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. Melanoma Research, 2018, 28, 380-389.	1.2	17
20	Micro<scp>RNA</scp>â€125a promotes resistance to <scp>BRAF</scp> inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell and Melanoma Research, 2017, 30, 328-338.	3.3	34
21	A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. Cancer Cell, 2017, 31, 804-819.e7.	16.8	233
22	TYRP1 mRNA goes fishing for miRNAs in melanoma. Nature Cell Biology, 2017, 19, 1311-1312.	10.3	12
23	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Molecular Cell, 2017, 68, 731-744.e9.	9.7	90
24	Mutation burden as a potential prognostic marker of melanoma progression and survival.. Journal of Clinical Oncology, 2017, 35, 9567-9567.	1.6	12
25	KrÃ¼ppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. Oncotarget, 2017, 8, 26298-26311.	1.8	12
26	A TGFÎ²â€“miR-182â€“BRCA1 axis controls the mammary differentiation hierarchy. Science Signaling, 2016, 9, ra118.	3.6	23
27	BET and BRAF inhibitors act synergistically against BRAFâ€mutant melanoma. Cancer Medicine, 2016, 5, 1183-1193.	2.8	41
28	Targeted next-generation sequencing of melanoma patient samples to reveal mutations in non-protein coding regions of targetable oncogenes.. Journal of Clinical Oncology, 2016, 34, 9559-9559.	1.6	0
29	Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.. Journal of Clinical Oncology, 2016, 34, 9524-9524.	1.6	0
30	Revisiting determinants of prognosis in cutaneous melanoma. Cancer, 2015, 121, 4108-4123.	4.1	75
31	Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Molecular Cell, 2015, 59, 75-88.	9.7	166
32	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	47
33	FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nature Cell Biology, 2015, 17, 322-332.	10.3	134
34	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clinical Cancer Research, 2015, 21, 4903-4912.	7.0	73
35	Limited miR-17-92 overexpression drives hematologic malignancies. Leukemia Research, 2015, 39, 335-341.	0.8	19
36	Abstract A12: Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. , 2015, , .		1

#	Article	IF	Citations
37	Control of Embryonic Stem Cell Identity by BRD4-Dependent Transcriptional Elongation of Super-Enhancer-Associated Pluripotency Genes. Cell Reports, 2014, 9, 234-247.	6.4	181
38	Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice. Molecular Cancer Therapeutics, 2014, 13, 1729-1739.	4.1	55
39	Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma.. Journal of Clinical Oncology, 2014, 32, 9072-9072.	1.6	0
40	Abstract 3708: microRNAs involved in BRAF inhibitor resistance. , 2014, , .		0
41	BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy. Cancer Research, 2013, 73, 6264-6276.	0.9	196
42	In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. Frontiers in Oncology, 2013, 3, 127.	2.8	9
43	Melanoma recurrence risk stratification using Bayesian systems biology modeling.. Journal of Clinical Oncology, 2013, 31, 9089-9089.	1.6	0
44	Targeting BET proteins in melanoma: A novel treatment approach.. Journal of Clinical Oncology, 2013, 31, 9091-9091.	1.6	1
45	MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis, 2012, 33, 1823-1832.	2.8	79
46	Expression of miR-16 is not a suitable reference for analysis of serum microRNAs in melanoma patients. Journal of Biomedical Science and Engineering, 2012, 05, 647-651.	0.4	4
47	Abstract 425: Targeting embryonic signaling pathways in melanoma. , 2012, , .		0
48	Newmouse models of melanoma metastasis and differences in brain tropism and metastatic growth pattern.. Journal of Clinical Oncology, 2012, 30, e19015-e19015.	1.6	0
49	MicroRNA alterations associated with BRAF status in melanoma.. Journal of Clinical Oncology, 2012, 30, 8565-8565.	1.6	0
50	Early alterations of microRNA expression to predict and modulate melanoma metastasis.. Journal of Clinical Oncology, 2012, 30, 8550-8550.	1.6	0
51	Identification of melanoma-specific alterations in cell surface glycosylation.. Journal of Clinical Oncology, 2012, 30, e19018-e19018.	1.6	0
52	miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis. Cancer Cell, 2011, 20, 104-118.	16.8	314
53	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. Cancer Research, 2011, 71, 2561-2571.	0.9	57
54	Abstract LB-342: MicroRNA-130b contributes to mesenchymal differentiation and leiomyosarcomagenesis. , 2011, , .		0

#	Article	IF	Citations
55	Abstract LB-340: Early alterations of microRNA expression predict and functionally impact melanoma metastasis. , 2011, , .		0
56	The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature, 2010, 468, 1105-1109.	27.8	345
57	Melanoma MicroRNA Signature Predicts Post-Recurrence Survival. Clinical Cancer Research, 2010, 16, 1577-1586.	7.0	204
58	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1814-1819.	7.1	506
59	Aneuploidy Advantages?. Science, 2008, 322, 692-693.	12.6	17
60	Mad2 Overexpression Promotes Aneuploidy and Tumorigenesis in Mice. Cancer Cell, 2007, 11, 9-23.	16.8	556